- 1 IL-1 Mediates Tissue Specific Inflammation and Severe Respiratory Failure In
- 2 Covid-19: Clinical And Experimental Evidence
- 3
- 4 Running heading: IL-1 bioactivity in COVID-19
- 5
- 6 Georgios Renieris¹, Eleni Karakike¹, Theologia Gkavogianni¹, Dionysia- Eirini
- 7 Droggiti¹, Dionysios Kafousopoulos¹, Mihai G. Netea^{2,3}, Jesper Eugen-Olsen⁴,
- 8 John Simard⁵, Evangelos J. Giamarellos-Bourboulis¹
- 9
- ¹⁰ ¹4th Department of Internal Medicine, National and Kapodistrian University of
- 11 Athens, Medical School, 124 62 Athens, Greece
- ¹² ²Immunology and Metabolism, Life & Medical Sciences Institute, University of
- 13 Bonn, 53115 Bonn, Germany
- ¹⁴ ³Department of Internal Medicine and Center for Infectious Diseases, Radboud
- 15 University, 6500 Nijmegen, the Netherlands
- ⁴Department of Clinical Research, Copenhagen University Hospital Hvidovre,
- 17 2650 Hvidovre, Denmark
- 18 ⁵XBiotech, 78744 Austin, Texas, USA
- 19

20 Correspondence

- 21 E. J. Giamarellos-Bourboulis, MD, PhD
- 22 4th Department of Internal Medicine, ATTIKON University General Hospital
- 23 1 Rimini Street 124 62, Athens, Greece
- 24 Tel: +30 210 58 31 994/ Fax: +30 210 53 26 446
- 25 E-mail: egiamarel@med.uoa.gr

26 **ABSTRACT**

27 Background: Acute respiratory distress syndrome (ARDS) in COVID-19 has been 28 associated with dysregulated immune responses leading to catastrophic 29 inflammation. The activation pathways remain to be fully elucidated. We investigated 30 the ability of circulating to induce dysregulated immune responses. 31 Materials & Methods: Calprotectin and high mobility group box 1 (HMGB1) were 32 associated with ARDS in 60 COVID-19 patients. In a second cohort of 40 COVID-19 33 patients calprotectin at hospital admission was associated with serum levels of 34 soluble urokinase plasminogen activator receptor (suPAR). A COVID-19 animal 35 model was developed by intravenous injection of plasma from healthy volunteers or 36 patients with COVID-19 ARDS into C57/BL6 mice once daily for 3 consecutive days. 37 In separate experiments, mice were treated with a) the IL-1 receptor antagonist 38 Anakinra or vehicle and b) Flo1-2a anti-murine anti-IL-1 α monoclonal antibody or the 39 specific anti-human IL-1 α antibody XB2001, or isotype controls. Mice were sacrificed 40 on day 4. Cytokines and myeloperoxidase (MPO) in tissues were measured. 41 **Results:** Calprotectin, but not HMGB1, was elevated ARDS. Higher suPAR readouts 42 indicated higher calprotectin levels. CHallenge of mice with COVID-19 plasma led to 43 inflammatory reactions in murine lung and intestines as evidenced by increased 44 levels of TNFα, IL-6, IFNγ and MPO. Anakinra treatment brought these levels down. 45 Similar decrease was found in mice treated with Flo1-2a but not with XB2001. 46 **Conclusion:** Circulating alarmins, specifically calprotectin, of critically ill COVID-19 47 patients induces tissue-specific inflammatory responses through an IL-1α mediated 48 mechanism. This could be attenuated through inhibition of IL-1 receptor or specific 49 inhibition of IL-1 α .

- 50 **Keywords**: calprotectin, tumor necrosis factor, interleukin-6, interleukin-1 α , suPAR,
- 51 acute respiratory distress syndrome (ARDS), severe respiratory failure, COVID-19

53 INTRODUCTION

- 54 A little over one year since the onset of the COVID-19 pandemic, more than
- 55 2.3 million deaths have been attributed to the virus
- 56 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Despite all
- 57 efforts to understand the disease, efforts are ongoing to elucidate what drives
- 58 progression in COVID-19 cases from lower respiratory tract infections (LRTI) to
- 59 acute respiratory distress syndrome (ARDS). We have suggested that the
- 60 deterioration from pneumonia to ARDS is the result of a complex immune
- dysregulation, which in about 25% of patients appears to be related to a macrophage
- 62 activation like syndrome; while in the remaining 75% of patients the mechanism
- 63 seems to involve an interleukin (IL)-6 receptor dependent dysregulation, with an

64 associated lymphopenia and a subset of cytokine over-producing monocytes that

65 show decreased human leukocyte antigen (HLA)-DR expression (1).

- 66 Recent data suggests that SARS-CoV-2 stimulates vicious pro-inflammatory
- 67 responses inducing NLRP3 inflammasome activation in monocytes and

macrophages (2). In the open-label phase II study SAVE (3), patients with LRTI

- 69 caused by SARS-CoV-2 and showing plasma concentrations of the biomarker
- suPAR (soluble urokinase plasminogen activator receptor) \geq 6 ng/ml were treated
- 71 with the recombinant human IL-1 receptor antagonist Anakinra. Anakinra is able to
- 52 block both IL-1 α and IL-1 β bioactivity at the level of their common receptor (4) and
- 73 prevent the development of ARDS.

The results of the SAVE trial led us to hypothesise that LRTI caused by
 SARS-CoV-2 can progress to ARDS. In this hypothesis, as a result of infection by
 SARS-CoV-2, patients over-produce IL-1α and other danger-associated molecular
 patterns (DAMPs) from their lung parenchyma. DAMPs trigger the release of IL-1β

78	and in combination with IL-1 α evoke strong innate immune pro-inflammatory
79	responses which lead to ARDS (1). In order to test our hypothesis, we used a three-
80	step approach. In the first step, we measured and found higher concentrations of the
81	DAMP calprotectin in the plasma of patients with ARDS than patients without ARDS.
82	In the second step, we measured and found that DAMP concentrations in the plasma
83	of patients with suPAR more than 6 ng/ml were significantly higher than that in
84	patients with suPAR less than 6 ng/ml. In the third step, we studied a COVID-19-like
85	animal model, where we prevented the development of strong pro-inflammatory
86	responses through inhibition of IL-1 signalling via Anakinra or anti-IL-1 α antibodies.
87	
88	
89	PATIENTS & METHODS
90	Clinical study
91	Plasma samples from a cohort of 60 patients with and without ARDS that was
92	determined to be caused by SARS-CoV (approval 30/20 by the National Ethics
93	Committee of Greece; approval IS 021-20 by the National Organization for
94	Medicines of Greece) and from 40 participants in the SAVE trial (suPAR-quided
95	
	Anakinra treatment for Validation of the risk and Early management of severe
96	Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19; EudraCT number 2020-001466-11; National Ethics
96 97	Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19; EudraCT number 2020-001466-11; National Ethics Committee approval 38/20; National Organization for Medicines approval ISO 28/20;
96 97 98	Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19; EudraCT number 2020-001466-11; National Ethics Committee approval 38/20; National Organization for Medicines approval ISO 28/20; ClinicalTrials.gov registration NCT04357366) were analyzed.
96 97 98 99	Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19; EudraCT number 2020-001466-11; National Ethics Committee approval 38/20; National Organization for Medicines approval ISO 28/20; ClinicalTrials.gov registration NCT04357366) were analyzed. Patients were enrolled after written informed consent was provided by
96 97 98 99 100	Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19; EudraCT number 2020-001466-11; National Ethics Committee approval 38/20; National Organization for Medicines approval ISO 28/20; ClinicalTrials.gov registration NCT04357366) were analyzed. Patients were enrolled after written informed consent was provided by themselves or by first-degree relatives in case of patients unable to consent. All
96 97 98 99 100	Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19; EudraCT number 2020-001466-11; National Ethics Committee approval 38/20; National Organization for Medicines approval ISO 28/20; ClinicalTrials.gov registration NCT04357366) were analyzed. Patients were enrolled after written informed consent was provided by themselves or by first-degree relatives in case of patients unable to consent. All patients were adults of either sex with positive molecular testing of SARS-CoV-2

103 infiltrates by chest X-ray or computed tomography of the chest. Exclusion criteria 104 were a) HIV-1 infection and b) neutropenia defined as less than 1,000 neutrophils/mm³. Blood was sampled on the day of hospital admission in the 105 106 emergencies. For patients admitted with ARDS, blood was collected within 24 hours 107 from mechanical ventilation (MV). Control blood samples were collected from healthy 108 volunteers matched for age and gender. 109 The following clinical variables were recorded: i) demographics; ii) severity 110 scores, namely Acute Physiology and Chronic Health Evaluation (APACHE) II score, 111 Charlson's Comorbidity Index (CCI) and Sequential Organ Failure Assessment 112 (SOFA) score; (iii) absolute blood cell counts, biochemistry, and blood gases; (iv) 113 and progression into ARDS during the entire hospital stay. ARDS was defined as a 114 ratio of partial oxygen pressure to fraction of inspired oxygen (PaO₂ / FiO₂) below 115 150 mmHg necessitating mechanical ventilation. 116 Five millilitres of whole blood was collected into a tube containing 117 ethylenediaminetetraacetic acid (EDTA) and centrifuged. Calprotectin (S100A8/A9); 118 high-mobility group box 1 (HMGB1); suPAR and ferritin were measured by enzyme-119 linked immunosorbent assays (ELISA) (InflaRx, Jena, Germany and Creative 120 Diagnostics, Shirley, NY, USA; suPARnostic, ViroGates, Lyngby, Denmark and 121 ORGENTEC Diagnostika GmbH, Mainz, Germany, respectively); and C-reactive 122 protein (CRP) was measured using a nephelometric assay (Behring, Berlin, 123 Germany). The lowest limits of detection were: 0.5 ng/ml for HMGB1; 1.1 ng/ml for 124 suPAR; 0.2 mg/l for CRP; and 75 ng/ml for ferritin. RNA isolation of SARS-CoV-125 2 was performed with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). 126 Reverse transcription of the viral RNA into cDNA and enrichment of the sequences 127 of interest via Real-time Polymerase Chain Reaction (PCR) was performed in the

128 Rotor-Gene Q instrument (Qiagen) using the SARS-CoV-2 reagent Viasure (CerTest

129 Biotec SL, Zaragoza, Spain).

130

131 Animal model of COVID-19 Pathogenic Inflammation

Animal experiments were conducted in the Unit of Animals for Medical and Scientific purposes of the University General Hospital "Attikon" (Athens, Greece). All experiments were licensed from the Greek veterinary directorate under the protocol number 471955/06-07-2020.

136 We studied 80 male and female C57BI6 mice (7-8 weeks old). Mice were 137 allowed to acclimate for seven days before beginning of the experiments. They were 138 housed in typical mouse cages, up to 5 mice per cage on 12-h dark/light cycle and 139 allowed free access to standard dry rodent diet and water. Analgesia was achieved 140 with paracetamol suppositories to avoid interactions with the immune system. 141 In order to develop a model of COVID-19-like inflammatory illness, mice were 142 treated intravenously (iv) with 100 µl of plasma from patients with ARDS due to 143 SARS-CoV-2 infection for 3 consecutive days; control mice were treated with 100 µl 144 of plasma from healthy volunteers for 3 consecutive days. On the fourth day, mice 145 were sacrificed by subcutaneous (sc) injection of 300 mg/kg ketamine, followed by 146 cervical dislocation. Under sterile conditions a midline abdominal incision was 147 performed. Then, segments of liver, lower lobe of the right lung, right kidney, ileum 148 (ca. 1 cm distally to the pyloric sphincter) and colon (ca. 1 cm proximally of the anal 149 ring) were excised and collected into sterile tubes with 1 ml NaCl 0.9%. The 150 intestinal samples were thoroughly flushed with NaCl 0.9% for removal of feces 151 before storage. The samples were weighed and homogenized.

152	Segments of spleens were gently squeezed and passed through a sterile filter
153	(250 mm, 12-13 cm, AlterChem Co, Athens, Greece) for the collection of
154	splenocytes. Peritoneal cells were retrieved by peritoneal lavage with 10 ml of cold
155	PBS containing 2 mmol/I of EDTA. After three serial washings, spleencells and
156	peritoneal cells were counted on Neubauer plates with trypan blue for exclusion of
157	dead cells. A total of 5 x 10^6 cells/ml were incubated in sterile 24-well plates in
158	RPMI-1640, supplemented with 2 mM glutamine, 10% fetal bovine serum, 100 U/ml
159	of penicillin G and 0.1 mg/ml of streptomycin, in the absence or presence of 10 ng/ml
160	lipopolysaccharide (LPS) of <i>Escherichia coli</i> O55:B5 or 5 x 10^5 cfu/ml heat killed
161	Candida α lbicans (HKCA). After 24 hours or 5 days of incubation at 37°C in 5% CO ₂ ,
162	the plates were centrifuged, and the supernatants were collected. Concentrations of
163	tumor necrosis factor alpha (TNF α), interferon gamma (IFN γ) and IL-6, IL-17A and
164	IL-22 in supernatants from tissue samples and spleencells were measured in
165	duplicate by an enzyme immunosorbent assay (ThermoFisher Scientific,
166	Massachussets, USA) according to the manufacturer's instructions. The lowest
167	detections limits were as follows: for TNF α 19 pg/ml; for IFN γ 16 pg/ml; for IL-6 10
168	pg/ml; for IL-17A 8 pg/ml; and for IL-22 16 pg/ml.
169	Myeloperoxidase (MPO) activity in all collected tissues was determined.
170	Tissue segments were homogenized with T-PER $\ensuremath{\mathbb{R}}$ (ThermoFisher Scientific) and
171	centrifuged at 10,000 rpm at 4°C. Then the homogenates were incubated in wells of
172	a 96-well plate at 37°C with 4.2 mM tetramethylbenzidine (Serva, Heidelberg,
173	Germany), 2.5 mM citrate, 5 mM NaH ₂ PO ₄ and 1.18 mM H ₂ O ₂ pH 5.0 at a final
174	volume of 150 $\mu l.$ After 5 minutes the reaction was terminated by adding 50 ml 0.18
175	M H_2SO_4 . Absorbance was read at 450 nm against blank wells. Results were
176	adjusted for tissue sample protein content on Bradford assay (Sigma-Aldrich) and

177 they were expressed as MPO units/mg protein/g.

178	Experiments were repeated in mice receiving in addition to i.v. plasma, a) 100
179	μ l sc of 10 mg/kg Anakinra (Swedish Orphan Biovitrum, Stockholm, Sweden) or 100
180	μI of 0.9% NaCl once daily for 3 days; and b) 100 μI intraperitoneally (ip) of 1000
181	$\mu g/ml$ (12) anti-murine IL-1 α antibody Flo1-2a or human IL- 1α antibody XB2001, or
182	murine isotype control (XBiotech, TX, USA).
183	In a separate experiment, mice treated with COVID-19 plasma for three days
184	were challenged on the fourth day ip with 1x10 ⁷ cfu/ml <i>E. coli</i> or <i>Acinetobacter</i>
185	baumannii. Survival was recorded every 12 hours for 7 days.
186	
187	Statistics
188	Categorical data were presented as frequencies and quantitative variables as
189	mean \pm SE. Comparisons between groups were done using the Fisher exact test for
190	categorical data. Comparison for quantitative data was performed using the Mann-
191	Whitney U test for two group comparisons and the one-way ANOVA with the
192	Bonferroni correction for multiple group comparison. Correlations were performed
193	using the Spearman's rank of order. Any p value below 0.05 was considered
194	statistically significant.
195	
196	RESULTS
197	Forty consecutive patients with COVID-19 who did not develop ARDS during
198	their hospital stay and 20 consecutive patients with ARDS were analyzed. Their

- demographics are shown in Table 1. Samples of 10 healthy volunteers were
- 200 analyzed as healthy controls. Serum calprotectin levels were significantly higher
- among patients with COVID-19 and ARDS (Figure 1A). HMGB1 concentrations did

202 not differ between patients with COVID-19 with and without ARDS (Figure 1B).

203 Elevated calprotectin levels COVID-19-related ARDS raised the question whether

204 calprotectin is released early among patients and may serve as a marker for patients

who will progress to ARDS.

206 suPAR was previously identified as an early predictor of ARDS progression in 207 patients with at least 6 ng/ml serum levels in the SAVE trial (3). To study of the early 208 increase of suPAR denotes increases of calcprotectin, calprotectin was measured in 209 40 patients screened for inclusion in SAVE trial. 20 patients were with suPAR 210 concentrations less than 6 ng/ml and 20 patients showed suPAR concentrations ≥ 6 211 ng/ml (Table 2). None of the patients with suPAR less than 6 ng/ml developed ARDS; 212 30% of those with suPAR \geq 6 ng/ml progressed into ARDS. Remarkably, patients with 213 suPAR concentrations \geq 6 ng/ml had significantly higher concentrations of 214 calprotectin (Figure 1C). A significant positive correlation between calprotectin and 215 suPAR was thus demonstrated (Figure 1D). These findings demonstrated that both 216 suPAR and calprotectin are reliable prognostic biomarkers in predicting the 217 development of severe respiratory failure in COVID-19. These findings also 218 suggested that DAMPs like calprotectin, released at early stages of clinical infection 219 are involved in mediating the progression of pneumonia into ARDS. 220 In order to investigate the mechanism by which calprotectin induces the 221 hyperinflammation related to COVID-19 associated respiratory failure, we sought to 222 design a COVID-19 murine model. Mice were challenged with plasma either from 223 healthy volunteers (HV) or from patients with ARDS of COVID-19. Plasma of COVID-224 19 patients led to organ-specific increase of cytokine concentrations. More precisely,

225 TNFα and MPO activity were specifically increased in the lung, ileum and colon of

mice challenged with COVID-19 plasma; IL-6 was upregulated in the lung and colon;

and IFNγ was upregulated in the lung (Figure 2A to D). These findings demonstrated
a compartmentalized inflammatory response in mice after challenging with COVID19 patient plasma.

230 DAMPs, like calprotectin, act on monocytes and macrophages and tend to 231 stimulate intense IL-1 responses. To provide evidence on the contribution of IL-1 232 stimulation, mice challenged with plasma from HV or COVID-19 patients were 233 treated with N/S or with Anakinra; the latter blocks both human and murine IL-1 α and 234 IL-1β. Treatment with Anakinra significantly reduced tissue concentrations of TNFa, 235 IL-6, IFN-y and MPO activity (Figure 3A to 3I). However, the observed inflammation 236 may have been mediated through human IL-1α present in the plasma of COVID-19 237 patients. To further clarify this, mice challenged with COVID-19 plasma were treated 238 with the anti-murine specific anti-IL-1α antibody Flo1-2a and with the human specific 239 anti-human IL-1α antibody XB2001, respectively. Treatment with Flo1-2a 240 significantly reduced tissue concentrations of TNF α , IL- 6, IFN γ and MPO activity in 241 contrast to treatment with XB2001 (Figure 4A to 4I). This suggests that the host-242 derived mouse IL-1 α and not any injected human IL-1 α was necessary to induce the 243 compartmentalized inflammation. 244 Treatment with Anakinra led to an increase in ex vivo production capacity of 245 IFNγ and TNFα, but not of IL-6, IL-17A or IL-22 from splenocytes following 246 stimulation with HKCA (Figure 5A to 5F and Figure S1A to S1D). HKCA targets 247 lymphocyte responses from splenocytes and the cytokine responses are compatible 248 with increase of Th1 responses following treatment with Anakinra. 249 The number of transcripts of core SARS-CoV-2 genes ORF1ab and N were 250 indirectly provided by the cycles (Ct) of PCR positivity in plasma samples that were

used for the induction of the COVID-19-like hyperinflammation in the murine model.

252 No correlation was found between Cts and the levels of TNF α , IL-6, IFN γ and MPO in 253 the lung of COVID-19 patients with ARDS due to COVID-19 (Figure S2). This suggests 254 that the hyperinflammation is independent from the viral load. In order to mimic hospital 255 acquired secondary bacterial infections among COVID-19 patients in murine, mice 256 treated for three consecutive days with COVID-19 plasma were further challenged 257 with A. baumannii or E. coli. Survival was significantly lower after challenging with A. 258 baumannii (Figure 3E). Observations coming from our prospective cohort of 134 259 ARDS patients revealed higher incidence of secondary infections by A. baumannii 260 when compared to other Gram-negative bacteria (Table S1, Figure S3). This further 261 supports the immunological similarities of the developed animal model to the human 262 infection.

263

264 **DISCUSSION**

This study presented evidence that severe respiratory failure in COVID-19 patients is possibly triggered by DAMPs, most likely calprotectin, which are released early after the interaction of SARS-CoV-2 with host cells. It may well be the case that calprotectin is this specific DAMP since circulating levels of HMGB1, another DAMP, do not follow those of calprotectin. DAMPs lead to a compartmentalized inflammation through enhancement of the production of pro-inflammatory cytokines IL-1 α and IL-1 β .

It has been clearly demonstrated that an impaired immune response is a core characteristic of patients who develop ARDS due to SARS-CoV-2 (5). The associated great increase in the mortality of these patients has turned the focus on potential therapeutic targets to disrupt the immune dysregulation. This necessitates a better understanding of the pathogenesis of COVID-19.

277 Calprotectin, a heterodimer of S100A8 and S100A9, is a protein secreted by 278 leukocytes. The upregulation of calprotectin expression has been associated with 279 various inflammatory processes such as inflammatory bowel disease, rheumatoid 280 arthritis, spondyloarthritis and cardiovascular disease in type 2 diabetes mellitus (6-281 9). Additionally, calprotectin is crucial for neutrophil accumulation and inflammation 282 in the lung parenchyma during bacterial community acquired pneumonia (10). 283 Recently, high levels of calprotectin in samples of COVID-19 patients were 284 correlated with disease severity and were associated with increased levels of 285 inflammatory cytokines and chemokines and myelopoiesis of abnormal myeloid cells 286 (11). In this study, we suggest calprotectin as a potential first element in the pathway 287 leading to ARDS in COVID-19 patients. Indeed, we found greater levels in patients 288 with ARDS compared to patients without ARDS. On the contrary, HMGB1, an 289 additional alarmin, which has been associated with sepsis pathogenesis and 290 outcome (12), did not significantly differ among patients with and without ARDS due 291 to COVID-19. Moreover, suPAR which is an early predictor of respiratory 292 deterioration in COVID-19 (3, 13) was indicative of patients with higher calprotectin 293 levels, suggesting that increased suPAR can be the biomarker of DAMP-induced 294 pathways in COVID-19. 295 SARS-CoV-2 uses the cellular surface protein angiotensin-converting enzyme 296 2 (ACE2) to bind and enter cells. However, the mouse ACE2 does not effectively

bind the viral spike protein (14). Therefore wild-type mice cannot be directly used as

a model to gain insight in COVID-19 pathophysiology. Mice over-expressing ACE2

have been used as a strategy to tackle this problem (15). While it is accepted that

300 the interaction of the spike protein of SARS-CoV-2 with human angiotensin

301 converting enzyme 2 (ACE2) is the first step for viral invasion in host cells of the

302	upper and lower respiratory tract (16), the ability of the virus to directly infect other
303	human tissues, where ACE2 is also expressed, such as the small intestine, kidneys,
304	and the heart, is a matter of dispute (17). In addition, we also need to understand the
305	pure immunological mechanisms of hyperinflammation in COVID-19. This is
306	introducing the need of COVID-19 models like the one developed after animal
307	challenge with human plasma. The model simulates the inflammatory reaction in
308	human SARS-CoV-2 infection since it provides compartmentalized
309	hyperinflammation of the lung.
310	Calprotectin acts through the Toll like receptor 4 (TLR4) and the receptor for
311	advanced glycation end-products (RAGE) and may prime for intracellular pro-IL-1 β
312	(18) which is subsequently cleaved by SARS-CoV-2 activated NLRP3 inflammasome
313	(2) into IL-1 β . Anakinra prevents the inflammatory action of both IL-1 α and IL-1 β by
314	blocking their cellular receptor. IL-1 α released during cell death is characterized by
315	an autocrine function enabling an amplifying loop of inflammation (19). Moreover, we
316	have shown that Anakinra enhances the Th1 response in mice and probably
317	improves viral clearance.
318	Our findings provide evidence that progression from LRTI by SARS-CoV-2 to
319	ARDS is a process which is mediated by DAMPs, like IL-1 α and calprotectin,
320	released following cell destruction. The early detection of the presence of circulating
321	DAMPs and blockade through IL-1a inhibition may represent a viable therapeutic
322	strategy. This is the hallmark of the efficacy of Anakinra - guided by the biomarker
323	suPAR - which led to a significant decrease in the incidence of ARDS in the SAVE
324	trial (3).

327 Acknowledgments

- 328 We thank Zhongli Xu, Katja Schubert, Marlen Hermann (InflaRx GmbH, Jena,
- 329 Germany) for the measurements of calprotectin in patient samples as well as for
- 330 their critical review of the manuscript.
- 331

332 Competing interests

- J. Eugen-Olsen is a cofounder, shareholder and CSO of ViroGates A7S, Denmark
- and is named inventor on patents on suPAR owned by Copenhagen University
- 335 Hospital Hvidovre, Denmark. He is granted by the Horizon 2020 European Grant
- 336 RISKinCOVID.
- 337 J. Simard is the CEO and founder of XBiotech.
- 338 M.G. Netea is a scientific founder of TTxD, and received research grants from GSK
- and ViiV Healthcare.
- 340 E.J. Giamarellos-Bourboulis has received honoraria from AbbVie USA, Abbott CH,
- 341 InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent
- 342 educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield,
- bioMérieux Inc, InflaRx GmbH, and XBiotech Inc.; and funding from the FrameWork
- 344 7 program HemoSpec (granted to the National and Kapodistrian University of
- 345 Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted
- to the National and Kapodistrian University of Athens), and the Horizon 2020
- 347 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of

348 Sepsis).

349

350 Funding

- 351 The study was funded in part by the Hellenic Institute for the Study of Sepsis and in
- 352 part by the Horizon 2020 grant RISKinCOVID. The funders had no role in the design,
- 353 collection, analysis and interpretation of data, writing, and decision to publish.

- ____

REFERENCES

377	1.	Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,
378		Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, Ntaganou
379		M, Kyriakopoulou M, Dimopoulos G, Koutsodimitropoulos I, Velissaris D,
380		Koufargyris P, Karageorgos A, Katrini K, Lekakis V, Lupse M, Kotsaki A, Renieris
381		G, Theodoulou D, Panou V, Koukaki E, Koulouris N, Gogos C, Koutsoukou A.
382		Complex immune dysregulation in COVID-19 patients with severe respiratory
383		failure. Cell Host Microbe. 2020;27:992-1000.e3.
384	2.	Rodrigues TS, de Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L,
385		Gonçalves AV, Perucello DB, Andrade WA, Castro R, Veras FP, Toller-Kawahisa
386		JE, Nascimento DC, de Lima MHF, Silva CMS, Caetite DB, Martins RB, Castro
387		IA, Pontelli MC, de Barros FC, do Amaral NB, Giannini MC, Bonjorno LP, Lopes
388		MIF, Santana RC, Vilar FC, Auxiliadora-Martins M, Luppino-Assad R, de Almeida
389		SCL, de Oliveira FR, Batah SS, Siyuan L, Benatti MN, Cunha TM, Alves-Filho
390		JC, Cunha FQ, Cunha LD, Frantz FG, Kohlsdorf T, Fabro AT, Arruda E, de
391		Oliveira RDR, Louzada-Junior P, Zamboni DS. Inflammasomes are activated in
392		response to SARS-CoV-2 infection and are associated with COVID-19 severity in
393		patients. J Exp Med. 2021;218:e20201707.
394	3.	Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G,
395		Gatselis N, Karakike E, Saridaki M, Loli G, Stefos A, Prasianaki D, Georgiadou S,
396		Tsachouridou O, Petrakis V, Tsiakos K, Kosmidou M, Lygoura V, Dareioti M,
397		Milionis C, Papanikolaou IC, Akinosoglou K, Myrodia DM, Gravvani A, Stamou A,
398		Gkavogianni T, Katrini K, Marantos T, Trontzas IP, Syrigos K, Chatzis L, Chatzis
399		S, Vechlidis N, Avgoustou C, Chalvatzis S, Kyprianou M, van der Meer JWM,

Eugen-Olsen J, Netea MG, Giamarellos-Bourboulis EJ. An open label trial of

401	Anakinra to prevent respiratory failure in COVID-19. eLife. 2021;10:e66125.
402	4. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS,
403	Begun J, Plantinga TS, Joosten LA, van der Meer JW, Chamilos G, Netea MG,
404	Xavier RJ, Dinarello CA, Romani L, van de Veerdonk FL. IL-1 receptor blockade
405	restores autophagy and reduces inflammation in chronic granulomatous disease
406	in mice and in humans. Proc Natl Acad Sci. 2014;111:3526–31.

- 407 5. Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of
- 408 COVID-19: Mechanisms underlying disease severity and progression.
- 409 *Physiology*. 2020;35:288-301.
- 410 6. Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H,
- 411 Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T. Detection of calprotectin
- in inflammatory bowel disease: Fecal and serum levels and immunohistochemical
- 413 localization. *Int J Mol Med.* 2018;41:107-118.
- 414 7. Azramezani Kopi T, Shahrokh S, Mirzaei S, Asadzadeh Aghdaei H, Amini
- 415 Kadijani A. The role of serum calprotectin as a novel biomarker in inflammatory
- 416 bowel diseases: a review study. *Gastroenterol Hepatol Bed Bench*. 2019;12:183-
- 417 **189**.

- 418 8. Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C,
- 419 Finckh A, Gabay C, Nissen MJ; physicians of the Swiss Clinical Quality
- 420 Management (SCQM) registry. Serum calprotectin: a promising biomarker in
- 421 rheumatoid arthritis and axial spondyloarthritis. *Arthritis Res Ther.* 2020;22:105.
- 422 9. Oosterwijk MM, Bakker SJL, Nilsen T, Navis G, Laverman GD. Determinants of
- 423 increased serum calprotectin in patients with type 2 diabetes mellitus. *Int J Mol*
- 424 *Sci.* 2020;21:8075.

- 425 10. Kotsiou OS, Papagiannis D, Papadopoulou R, Gourgoulianis KI. Calprotectin in
- 426 lung diseases. *Int J Mol Sci*. 2021;22:1706.
- 427 11. Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C,
- 428 Hénon C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C,
- 429 Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D,
- 430 Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V,
- 431 Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I,
- 432 Barlesi F, Marabelle A, Pène F, Gachot B, André F, Zitvogel L, Ginhoux F,
- 433 Fontenay M, Solary E. Elevated calprotectin and abnormal myeloid cell subsets
- discriminate severe from mild COVID-19. *Cell*. 2020;182:1401-1418.e18.
- 435 12. Karakike E, Adami ME, Lada M, Gkavogianni T, Koutelidakis IM, Bauer M,
- 436 Giamarellos-Bourboulis EJ, Tsangaris I. Late peaks of HMGB1 and sepsis
- 437 outcome: evidence for synergy with chronic inflammatory disorders. *Shock*.
- 438 2019;52:334-339.
- 439 13. Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-
- 440 Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an
- 441 early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
- 442 *Crit Care*. 2020;24:187.
- 14. Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by
- 444 novel coronavirus from Wuhan: an analysis based on decade-long structural
- studies of SARS coronaviru**s.** *J Virol*. 2020;94:e00127-20.
- 446 15. Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Riveros-Balta AX,
- 447 Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I,
- 448 Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D,
- 449 Finch CL, Frieman MB, Graham BS, Gralinski LE, Guilfoyle K, Haagmans BL,

450	Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra WB, Knezevic I,
451	Krause PR, Kuhn JH, Le Grand R, Lewis MG, Liu WC, Maisonnasse P, McElroy
452	AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B,
453	Rodríguez E, Rogers TF, Salguero FJ, Schotsaert M, Stittelaar KJ, Thibaut HJ,
454	Tseng CT, Vergara-Alert J, Beer M, Brasel T, Chan JFW, García-Sastre A, Neyts
455	J, Perlman S, Reed DS, Richt JA, Roy CJ, Segalés J, Vasan SS, Henao-
456	Restrepo AM, Barouch DH. Animal models for COVID-19. Nature. 2020;586:509-
457	515.
458	16. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor
459	usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol.
460	2020;5:562-569.
461	17.Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M,
462	Medaglia C, Li H, Deczkowska A, Zhang S, Schwikowski B, Zhang Z, Amit I.
463	Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell.
464	2020;181:1475-1488.e12.
465	18. Vogl T, Stratis A, Wixler V, Völler T, Thurainayagam S, Jorch SK, Zenker S,
466	Dreiling A, Chakraborty D, Fröhling M, Paruzel P, Wehmeyer C, Hermann S,
467	Papantonopoulou O, Geyer C, Loser K, Schäfers M, Ludwig S, Stoll M,
468	Leanderson T, Schultze JL, König S, Pap T, Roth J. Autoinhibitory regulation of
469	S100A8/S100A9 alarmin activity locally restricts sterile inflammation. J Clin
470	Invest. 2018;128:1852-66.
471	19. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related
472	cytokines in the regulation of inflammation and immunity. Immunity. 2019;50:778-
473	795.
474 475	

	No ARDS (n=40)	ARDS (n=20)	p-value
Age (years, mean \pm SD) $^{\#}$	57.3 ±14.85	66.60 ± 11.45	0.020 [#]
Male gender (n, %)	33 (82.5)	17 (85.0)	0.559 ²
CCI (mean \pm SD) [#]	1.85 ± 1.66	3.55 ± 2.56	0.012#
APACHE II score (mean \pm SD) [#]	5.50 ± 3.11	10.05 ± 5.07	0.001 [#]
SOFA (mean \pm SD) [#]	1.87 ± 1.66	3.35 ± 1.06	0.001#
Main comorbidities (n, %)			
Type 2 diabetes mellitus	6 (15.0)	6 (30.0)	0.189
Congestive heart failure	1 (2.5)	2 (10.0)	0.255
Coronary heart disease	1 (2.5)	4 (20.0)	0.0382
Chronic renal disease	1 (2.5)	0 (0)	0.6672
COPD	4 (10.0)	3 (15.0)	0.6762
Laboratory values (mean ± SD)			
White blood cells (mm ³)	6098.46 ± 2102.44	8758.00 ± 3992.08	0.003#
Absolute neutrophil counts (mm ³)	4535.52 ± 2110.35	7437.75 ± 3762.13	0.001 [#]
Absolute lymphocyte counts (mm ³)	1065.98 ± 419.86	810.04 ± 426.46	0.025 [#]
Platelets (x 10 ³ , mm ³)	191.2 ± 85.6	178.3 ± 54.9	0.389 [#]
C-reactive protein (mg/l)	124.55 ± 100.73	206.38 ± 85.96	0.014 [#]
Fibrinogen (mg/dl)	510.59 ± 172.91	611.20 ± 199.78	0.262#
Ferritin (ng/ml)	1136.05 ± 1022.05	1288.83 ± 573.13	0.381 [#]
Procalcitonin (ng/ml)	0.25 ± 0.39	0.38 ± 0.46	0.280 [#]
D-dimers (ng/ml)	599.76 ± 364.72	763.00 ± 702.42	0.464 [#]
AST (U/I)	41.32 ± 26.62	64.80 ± 108.08	0.502#
ALT (U/I)	39.33 ± 34.24	52.80 ± 74.30	0.822#
Creatinine (mg/dl)	0.89 ± 0.18	1.29 ± 1.16	0.006#
Total bilirubin (mg/dl)	0.59 ± 0.54	5.25 ± 18.34	0.211 [#]

Table 1. Baseline clinical and laboratory characteristics of patients according to the development of ARDS due to pneumonia by the SARS-CoV-2 coronavirus

<u>Abbreviations</u>: SD: standard deviation; APACHE: acute physiology and chronic health evaluation; CCI: Charlson's comorbidity index; SOFA: sequential organ failure; COPD: chronic obstructive pulmonary disease; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ARDS: acute respiratory distress syndrome [®]Comparison by Fischer exact test; [#]Comparison by the Mann- Whitney U test.

476

urokinase plasminogen activator receptor (suPAR)				
	suPAR < 6 ng/ml (n=20)	suPAR ≥ 6 ng/ml (n=20)	p-value	
Age (years, mean \pm SD) [#]	46.25 ±17.63	68.30 ± 9.27	6 x 10 ^{-5#}	
Male gender (n, %)	13 (65.0)	13 (65.0)	1.000	
CCI (mean \pm SD) [#]	3.56 ± 1.62	5.13 ± 0.99	0.022#	
APACHE II score (mean \pm SD) [#]	7.28 ± 3.43	6.69 ± 5.25	0.953 [#]	
SOFA (mean \pm SD) [#]	0.86 ± 1.07	2.61 ± 1.20	0.004 [#]	
ARDS (n, %)	0 (0.0)	6 (30)	3 x 10 ⁻⁶ ℤ	
Main comorbidities (n, %)				
Type 2 diabetes mellitus	1 (5.0)	4 (20.0)	0.342	
Congestive heart failure	0 (0)	1 (5.0)	0.500	
Coronary heart disease	1 (5.0)	3 (15.0)	0.658ℤ	
COPD	0 (0)	1 (5.0)	0.506	
Laboratory values (mean \pm SD)				
White blood cells (mm ³)	6007.14 ± 1500.55	7578.88 ± 3201.64	0.220 [#]	
Absolute neutrophil counts (mm ³)	3573.30 ± 1723.14	5833.80 ± 2988.62	0.055#	
Absolute lymphocyte counts (mm ³)	2233.86 ± 1872.39	1203.26 ± 614.70	0.198 [#]	
Platelets (x 10 ³ , mm ³)	261.8 ± 133.8	212.1 ± 68.2	0.574 [#]	
C-reactive protein (mg/l)	35.69 ± 53.43	89.19 ± 82.45	0.083 [#]	
Fibrinogen (mg/dl)	352.00 ± 59.24	612.22 ± 187.67	0.003#	
Ferritin (ng/ml)	283.41 ± 244.73	882.90 ± 595.75	0.024 [#]	
Procalcitonin (ng/ml)	0.06 ± 0.05	0.36 ± 0.36	0.133 [#]	
D-dimers (ng/ml)	421.67 ± 324.10	1407.79 ± 3251.55	0.207 [#]	
AST (U/I)	22.57 ± 6.68	46.44 ± 29.49	0.041 [#]	
ALT (U/I)	27.14 ± 14.37	38.67 ± 27.78	0.458 [#]	
Creatinine (mg/dl)	0.92 ± 0.27	0.97 ± 0.34	0.883 [#]	
Total bilirubin (mg/dl)	0.259 ± 0.11	1.54 ± 2.06	0.001#	

Table 2. Baseline clinical and laboratory characteristics of patients with pneumonia by SARS-CoV-2 coronavirus according to the measured levels of circulating soluble urokinase plasminogen activator receptor (suPAR)

<u>Abbreviations</u>: SD: standard deviation; APACHE: acute physiology and chronic health evaluation; CCI: Charlson's comorbidity index; SOFA: sequential organ failure; ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; AST: aspartate aminotransferase; ALT: alanine aminotransferase.

[®]Comparison by Fischer exact test; [#]Comparison by the Mann- Whitney U test.

478

480 **FIGURE LEGENDS**

- 481 Figure 1 Calprotectin is increased in patients with ARDS due to COVID-19
- 482 A-B) Concentrations of calprotectin (S100A8/A9) and high mobility group box 1
- 483 (HMGB1) were measured in the plasma from healthy volunteers; from patients with
- 484 COVID- 19 who did not develop ARDS during follow-up on the day of hospital
- 485 admission; and from patients with ARDS by COVID- 19 on the first day of ARDS.
- 486 Comparison by the Mann Whitney U test; ns non- significant; p< 0.05; p< 0.01; 22
- 487 p< 0.001; 222; p< 0.0001.
- 488 Panels C and D) suPAR was measured in 40 patients screened for participation in the
- 489 SAVE trial (3). None of the patients with suPAR less than 6 ng/ml developed acute
- 490 respiratory distress syndrome (ARDS), whereas 6 patients (30%) with suPAR 6 ng/ml or
- 491 more developed ARDS.
- 492 C) Concentrations of calprotectin in 20 patients with suPAR less than 6 ng/ml and in 20
- 493 patients with suPAR 6 ng/ml or more. Comparison by the Mann Whitney U test; p <
- 494 0.05.
- 495 D) Correlation of levels of suPAR with plasma calprotectin on day of admission
- 496 Spearman rank correlation coefficients (r_s), interpolation lines and p-values are

497 provided.

- 498
- 499

500 Figure 2 A COVID- like animal model of compartmentalized hyperinflammation

- 501 C57Bl6 mice were injected intravenously (i.v.) with plasma of healthy volunteers or
- 502 patients with ARDS due to COVID-19 for three consecutive days. Mice were sacrificed
- 503 on day 4. Tissue concentrations of A) tumor necrosis factor alpha (TNFα); B) Interleukin
- 504 (IL)-6; C) Interferon gamma (IFNy) and D) myeloperoxidase (MPO) activity were

505 determined. Comparison by the Mann Whitney U test; ns non-significant; p< 0.05; P

506 p< 0.01; 222 p< 0.0001.

507 E) C57BI6 mice were injected intravenously (i.v.) with plasma of healthy volunteers or 508 patients with ARDS due to COVID-19 for three consecutive days. On day 4 mice were 509 challenged intraperitoneally (i.p.) with *E. coli* or *A. baumannii*. Survival comparison by 510 the log-rank test and the respective p-value are provided. 511 512 513 Figure 3 IL-1 inhibition attenuates the compartmentalized hyperinflammation in a 514 **COVID-like murine model** 515 In a COVID-like infection model, C57BI6 mice were challenged intravenously (i.v.) with 516 plasma of healthy volunteers or patients with ARDS due to COVID-19 for three 517 consecutive days. In separate experiments, on each day of plasma challenge, mice 518 were treated with Anakinra, which inhibits human and murine IL-1, or vehicle. Mice were 519 sacrificed on day 4. A-C) Tumor necrosis factor alpha (TNF α); D-E) Interleukin (IL) -6; F) 520 Interferon gamma (IFNy) and G-I) myeloperoxidase (MPO) activity was determined in 521 tissues. Comparison by the Mann Whitney U test: ns non-significant: ^a p< 0.05: ^a p< 522 0.01. 523 524

525 Figure 4 Murine IL-1α drives the hyperinflammation caused by SARS-CoV-2

526 In a COVID- like infection model, C57BI6 mice were challenged intravenously (i.v.) with

527 plasma of patients with ARDS due to COVID-19 for three consecutive days. In separate

528 experiments, on each day of plasma challenge, mice were treated with Flo1-2a anti-

529 murine IL-1α antibody or XB2001 human IL- 1α antibody or murine isotype control

- 530 for Flo1-2a. Mice were sacrificed on day 4. A-C) Tumor necrosis factor alpha (TNFα);
- 531 D-E) Interleukin (IL) -6; F) Interferon gamma (IFNy) and G-I) myeloperoxidase (MPO)
- 532 activity was determined in tissues. Comparison by the Mann Whitney U test; ns non-
- 533 significant; [□] p< 0.05; [□] p< 0.01; [□] p< 0.001.
- 534
- 535

536 Figure 5 IL-1 inhibition primes Th1 responses in COVID-19

- 537 A-C) In a COVID- like infection model, C57BI6 mice were treated intravenously (i.v.) with
- 538 plasma of healthy volunteers or patients with ARDS due to COVID-19 for three
- 539 consecutive days. Mice were sacrificed on day 4. Splenocytes were isolated and
- 540 incubated with heat killed *C. albicans* for the production of interferon-gamma (IFNγ),
- 541 tumour necrosis factor-alpha (TNFα) and interleukin (IL)-6.
- 542 D-F) In a COVID- like infection model, C57BI6 mice were treated intravenously (i.v.) with
- 543 plasma of patients with ARDS due to COVID-19 with or without treatment with the IL-1
- 544 receptor inhibitor Anakinra for three consecutive days.
- 545 Mice were sacrificed on day 4. Splenocytes were isolated and incubated with heat killed
- 546 *C. albicans* for the production of IFNγ, TNFα and IL-6. Comparison by the Mann
- 547 Whitney U test; ns non-significant; $^{\square}$ p< 0.05; $^{\square}$ p< 0.01.
- 548

Α.





C.



D.

В.

















contrapastic



Ε.

Η.

F.

١.



G.

ſ

HN Plasma



ō

COND-19-plasma

Anakina

HN Plasma

* NIS

* ARRHINS





MPO ileum



MPO colon













G.









